| |
|
|
|
Catabasis Pharmaceuticals Inc.  
|
|
8.01 -0.21 (-0.03%) |
05-22 16:00 |
|
Open: |
8.11 |
Pre close: |
8.22 |
Target:
|
9.66 
|
|
High: |
8.28 |
Low: |
7.75 |
Resistance:
|
8.27
8.90
|
|
Volume: |
106,326 |
Market Cap: |
92M |
Support:
|
7.26
6.04
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
8.04
|
MACD |
MACD(12,26):
|
0.08 |
|
MA(20): |
7.83 |
Signal(12,26,9): |
0.07  |
|
MA(100): |
6.53 |
Stochastic Oscillator |
%K(14,3):
|
45.12 |
|
MA(250): |
7.43 |
%D(3): |
44.65 |
|
Average Volume(K) |
3-Month: |
18757
|
52-Week |
High:
|
17.60 |
|
10-Days: |
14370 |
Low: |
3.60 |
|
RSI |
RSI(14):
|
52.27 |
Change(%): |
-49.3 |
|
Financials, Statistics and Valuation |
|
EPS |
-6.550 |
Return on Equity (ttm) |
-78.7 |
Shares Out. (M) |
11.50 |
|
EPS Est. Current Year |
-1.390 |
Return on Assets (ttm) |
-68.2 |
Shares Float (M) |
10.99 |
|
EPS Est. Next Year |
-1.100 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
-0.330 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
42.70 |
|
Forward EPS |
-1.190 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
0 |
|
Book Value (p.s.) |
1.900 |
EBITDA (p.s.) |
0.000 |
P/E |
-1.22 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
4.22 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-23.46 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-13.71 |
P/CF |
-3.93 |
|
|
|
|
|
|
